ICT-107 is the company’s dendritic cell based cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM).
The study will enroll approximately 100 patients, and will be conducted at about 15 clinical trial centres in the US in collaboration with leading experts and opinion leaders in neuro-oncology.
The Phase I clinical study of ICT-107 in GBM had newly diagnosed patients who received the vaccine in addition to the standard care of surgery, radiation and chemotherapy demonstrate a one year overall survival of 100 percent, and a two year survival of 80 percent.
NJ Neuroscience Institute director of Neuro-Oncology Joseph Landolfi said that this enrollment represents a hopeful step towards the development of a treatment for an aggressive type of brain tumour.